Article: VALIRX PLC - European Technology Patent for Nucleosomics.

 
For immediate release - 7.00am, 12th November 2007 
 
  ValiRx Plc 
 
  ("ValiRx") 
 
  European Technology Patent for Nucleosomics 
 
ValiRx (AIM: VAL), the cancer therapeutics company, today announces that 
following the announcement on 15 October 2007 regarding the signing of a full 
license agreement with Chroma Therapeutics Ltd ("Chroma") to commercialise 
Nucleosomics1, a non-invasive diagnostic technology patent developed by Chroma, 
ValiRx has been allowed the European patent for its Nucleosomics technology 
patent application. 
 
Nucleosomics complements ValiRx's existing cancer diagnostics ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!